<SEC-DOCUMENT>0000950170-25-038901.txt : 20250313
<SEC-HEADER>0000950170-25-038901.hdr.sgml : 20250313
<ACCEPTANCE-DATETIME>20250313172431
ACCESSION NUMBER:		0000950170-25-038901
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250224
FILED AS OF DATE:		20250313
DATE AS OF CHANGE:		20250313

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			MACAN WILLIAM ANDREW
		CENTRAL INDEX KEY:			0001758584
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38546
		FILM NUMBER:		25736933

	MAIL ADDRESS:	
		STREET 1:		24275 KATY FREEWAY, SUITE 600
		CITY:			KATY
		STATE:			TX
		ZIP:			77494

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neuronetics, Inc.
		CENTRAL INDEX KEY:			0001227636
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		3222 PHOENIXVILLE PIKE
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		877-600-7555

	MAIL ADDRESS:	
		STREET 1:		3222 PHOENIXVILLE PIKE
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEURONETICS INC
		DATE OF NAME CHANGE:	20030416
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4/A
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2025-02-24</periodOfReport>

    <dateOfOriginalSubmission>2025-02-26</dateOfOriginalSubmission>

    <issuer>
        <issuerCik>0001227636</issuerCik>
        <issuerName>Neuronetics, Inc.</issuerName>
        <issuerTradingSymbol>STIM</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001758584</rptOwnerCik>
            <rptOwnerName>MACAN WILLIAM ANDREW</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O NEURONETICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>3222 PHOENIXVILLE PIKE</rptOwnerStreet2>
            <rptOwnerCity>MALVERN</rptOwnerCity>
            <rptOwnerState>PA</rptOwnerState>
            <rptOwnerZipCode>19355</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>EVP, GC, CCO and CS</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Performance Restricted Stock Unit</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-02-24</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>78750</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2025-12-31</value>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2028-07-01</value>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>78750</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>78750</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The Form 4 filed on February 26, 2025 inadvertently reported that the performance restricted stock unit (&quot;PRSU&quot;) award granted on February 24, 2025 vests in 1/3 tranches on December 31, 2027, 2026 and 2027, subject to satisfaction of the applicable performance metrics and continuous service of the Reporting Person through such date. The correct vesting dates are December 31, 2025, 2026 and 2027. The Form 4 also reported that the Reporting Person receives a percentage of each vesting if the Issuer's year-end cash balance is between 80% (the &quot;Threshold Achievement&quot;) and 110% of the target for each vesting year. However, the correct Threshold Achievement is 90%. The number of shares reflected in column 7 assumes the maximum potential vest in each vesting year.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Patrick Devine, as Attorney-in-Fact</signatureName>
        <signatureDate>2025-03-13</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
